☰

Alison C. Donnelly, Ph.D. - Publications

Affiliations: 
2011 Medicinal Chemistry University of Kansas, Lawrence, KS, United States 
Tree Info Similar researchers PubMed Report error

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2012 Iwai A, Bourboulia D, Mollapour M, Jensen-Taubman S, Lee S, Donnelly AC, Yoshida S, Miyajima N, Tsutsumi S, Smith AK, Sun D, Wu X, Blagg BS, Trepel JB, Stetler-Stevenson WG, et al. Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells. Cell Cycle (Georgetown, Tex.). 11: 3649-55. PMID 22935698 DOI: 10.4161/Cc.21926  0.724
2011 Eskew JD, Sadikot T, Morales P, Duren A, Dunwiddie I, Swink M, Zhang X, Hembruff S, Donnelly A, Rajewski RA, Blagg BS, Manjarrez JR, Matts RL, Holzbeierlein JM, Vielhauer GA. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. Bmc Cancer. 11: 468. PMID 22039910 DOI: 10.1186/1471-2407-11-468  0.707
2011 Samadi AK, Zhang X, Mukerji R, Donnelly AC, Blagg BS, Cohen MS. A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells. Cancer Letters. 312: 158-67. PMID 21924824 DOI: 10.1016/J.Canlet.2011.07.031  0.651
2011 Zhao H, Donnelly AC, Kusuma BR, Brandt GE, Brown D, Rajewski RA, Vielhauer G, Holzbeierlein J, Cohen MS, Blagg BS. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. Journal of Medicinal Chemistry. 54: 3839-53. PMID 21553822 DOI: 10.1021/Jm200148P  0.686
2011 Matts RL, Brandt GE, Lu Y, Dixit A, Mollapour M, Wang S, Donnelly AC, Neckers L, Verkhivker G, Blagg BS. A systematic protocol for the characterization of Hsp90 modulators. Bioorganic & Medicinal Chemistry. 19: 684-92. PMID 21129982 DOI: 10.1016/J.Bmc.2010.10.029  0.653
2010 Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee MJ, Lee S, Morra G, Bourboulia D, Scroggins BT, Colombo G, Blagg BS, Panaretou B, Stetler-Stevenson WG, Trepel JB, et al. Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Molecular Cell. 37: 333-43. PMID 20159553 DOI: 10.1016/J.Molcel.2010.01.005  0.671
2010 Matthews SB, Vielhauer GA, Manthe CA, Chaguturu VK, Szabla K, Matts RL, Donnelly AC, Blagg BS, Holzbeierlein JM. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. The Prostate. 70: 27-36. PMID 19739131 DOI: 10.1002/Pros.21035  0.663
2010 Donnelly AC, Zhao H, Reddy Kusuma B, Blagg BSJ. Cytotoxic sugar analogues of an optimized novobiocin scaffold Medchemcomm. 1: 165-170. DOI: 10.1039/C0Md00063A  0.681
2009 Shelton SN, Shawgo ME, Matthews SB, Lu Y, Donnelly AC, Szabla K, Tanol M, Vielhauer GA, Rajewski RA, Matts RL, Blagg BS, Robertson JD. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Molecular Pharmacology. 76: 1314-22. PMID 19741006 DOI: 10.1124/Mol.109.058545  0.692
2008 Donnelly A, Blagg BS. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Current Medicinal Chemistry. 15: 2702-17. PMID 18991631 DOI: 10.2174/092986708786242895  0.703
2008 Donnelly AC, Mays JR, Burlison JA, Nelson JT, Vielhauer G, Holzbeierlein J, Blagg BS. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. The Journal of Organic Chemistry. 73: 8901-20. PMID 18939877 DOI: 10.1021/Jo801312R  0.716
Show low-probability matches.